The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Epilepsy Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
Epilepsy is a chronic neurological disorder that cause recurrent unprovoked seizures, characterized by brief and undetectable episodes of involuntary movement involving either a body part (partial) or the entire body (generalized).
The global Epilepsy Therapeutics market size is expected to reach US$ 5227.3 million by 2029, growing at a CAGR of 3.2% from 2023 to 2029. The market is mainly driven by the significant applications of Epilepsy Therapeutics in various end use industries. The expanding demands from the Hospitals, Neurology Centers, Home Care Settings and Ambulatory Surgical Centers, are propelling Epilepsy Therapeutics market. Anti-epileptic Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Dietary Supplements segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Epilepsy Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Epilepsy Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Epilepsy Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Epilepsy Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Epilepsy Therapeutics covered in this report include Abbott Laboratories, Cephalon, Novartis, Pfizer, Johnson & Johnson, GlaxoSmithKline, Sanofi, Sunovion Pharmaceuticals and Bausch Health, etc.
The global Epilepsy Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott Laboratories
Cephalon
Novartis
Pfizer
Johnson & Johnson
GlaxoSmithKline
Sanofi
Sunovion Pharmaceuticals
Bausch Health
Takeda
Global Epilepsy Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Epilepsy Therapeutics market, Segment by Type:
Anti-epileptic Drugs
Dietary Supplements
Vagal Nerve Stimulation
Surgical Therapies
Global Epilepsy Therapeutics market, by Application
Hospitals
Neurology Centers
Home Care Settings
Ambulatory Surgical Centers
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Epilepsy Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Epilepsy is a chronic neurological disorder that cause recurrent unprovoked seizures, characterized by brief and undetectable episodes of involuntary movement involving either a body part (partial) or the entire body (generalized).
The global Epilepsy Therapeutics market size is expected to reach US$ 5227.3 million by 2029, growing at a CAGR of 3.2% from 2023 to 2029. The market is mainly driven by the significant applications of Epilepsy Therapeutics in various end use industries. The expanding demands from the Hospitals, Neurology Centers, Home Care Settings and Ambulatory Surgical Centers, are propelling Epilepsy Therapeutics market. Anti-epileptic Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Dietary Supplements segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Epilepsy Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Epilepsy Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Epilepsy Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Epilepsy Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Epilepsy Therapeutics covered in this report include Abbott Laboratories, Cephalon, Novartis, Pfizer, Johnson & Johnson, GlaxoSmithKline, Sanofi, Sunovion Pharmaceuticals and Bausch Health, etc.
The global Epilepsy Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott Laboratories
Cephalon
Novartis
Pfizer
Johnson & Johnson
GlaxoSmithKline
Sanofi
Sunovion Pharmaceuticals
Bausch Health
Takeda
Global Epilepsy Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Epilepsy Therapeutics market, Segment by Type:
Anti-epileptic Drugs
Dietary Supplements
Vagal Nerve Stimulation
Surgical Therapies
Global Epilepsy Therapeutics market, by Application
Hospitals
Neurology Centers
Home Care Settings
Ambulatory Surgical Centers
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Epilepsy Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Epilepsy Therapeutics
1.1 Epilepsy Therapeutics Market Overview
1.1.1 Epilepsy Therapeutics Product Scope
1.1.2 Epilepsy Therapeutics Market Status and Outlook
1.2 Global Epilepsy Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Epilepsy Therapeutics Market Size by Region (2018-2029)
1.4 Global Epilepsy Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Epilepsy Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Epilepsy Therapeutics Market Size (2018-2029)
1.6.1 North America Epilepsy Therapeutics Market Size (2018-2029)
1.6.2 Europe Epilepsy Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Epilepsy Therapeutics Market Size (2018-2029)
1.6.4 Latin America Epilepsy Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Epilepsy Therapeutics Market Size (2018-2029)
2 Epilepsy Therapeutics Market by Type
2.1 Introduction
2.1.1 Anti-epileptic Drugs
2.1.2 Dietary Supplements
2.1.3 Vagal Nerve Stimulation
2.1.4 Surgical Therapies
2.2 Global Epilepsy Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Epilepsy Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Epilepsy Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Epilepsy Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Epilepsy Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Epilepsy Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Epilepsy Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Epilepsy Therapeutics Revenue Breakdown by Type (2018-2029)
3 Epilepsy Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Neurology Centers
3.1.3 Home Care Settings
3.1.4 Ambulatory Surgical Centers
3.2 Global Epilepsy Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Epilepsy Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Epilepsy Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Epilepsy Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Epilepsy Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Epilepsy Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Epilepsy Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Epilepsy Therapeutics Revenue Breakdown by Application (2018-2029)
4 Epilepsy Therapeutics Competition Analysis by Players
4.1 Global Epilepsy Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Epilepsy Therapeutics as of 2022)
4.3 Date of Key Players Enter into Epilepsy Therapeutics Market
4.4 Global Top Players Epilepsy Therapeutics Headquarters and Area Served
4.5 Key Players Epilepsy Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Epilepsy Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Abbott Laboratories
5.1.1 Abbott Laboratories Profile
5.1.2 Abbott Laboratories Main Business
5.1.3 Abbott Laboratories Epilepsy Therapeutics Products, Services and Solutions
5.1.4 Abbott Laboratories Epilepsy Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Abbott Laboratories Recent Developments
5.2 Cephalon
5.2.1 Cephalon Profile
5.2.2 Cephalon Main Business
5.2.3 Cephalon Epilepsy Therapeutics Products, Services and Solutions
5.2.4 Cephalon Epilepsy Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Cephalon Recent Developments
5.3 Novartis
5.3.1 Novartis Profile
5.3.2 Novartis Main Business
5.3.3 Novartis Epilepsy Therapeutics Products, Services and Solutions
5.3.4 Novartis Epilepsy Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Pfizer Recent Developments
5.4 Pfizer
5.4.1 Pfizer Profile
5.4.2 Pfizer Main Business
5.4.3 Pfizer Epilepsy Therapeutics Products, Services and Solutions
5.4.4 Pfizer Epilepsy Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Pfizer Recent Developments
5.5 Johnson & Johnson
5.5.1 Johnson & Johnson Profile
5.5.2 Johnson & Johnson Main Business
5.5.3 Johnson & Johnson Epilepsy Therapeutics Products, Services and Solutions
5.5.4 Johnson & Johnson Epilepsy Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Johnson & Johnson Recent Developments
5.6 GlaxoSmithKline
5.6.1 GlaxoSmithKline Profile
5.6.2 GlaxoSmithKline Main Business
5.6.3 GlaxoSmithKline Epilepsy Therapeutics Products, Services and Solutions
5.6.4 GlaxoSmithKline Epilepsy Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 GlaxoSmithKline Recent Developments
5.7 Sanofi
5.7.1 Sanofi Profile
5.7.2 Sanofi Main Business
5.7.3 Sanofi Epilepsy Therapeutics Products, Services and Solutions
5.7.4 Sanofi Epilepsy Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Sanofi Recent Developments
5.8 Sunovion Pharmaceuticals
5.8.1 Sunovion Pharmaceuticals Profile
5.8.2 Sunovion Pharmaceuticals Main Business
5.8.3 Sunovion Pharmaceuticals Epilepsy Therapeutics Products, Services and Solutions
5.8.4 Sunovion Pharmaceuticals Epilepsy Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Sunovion Pharmaceuticals Recent Developments
5.9 Bausch Health
5.9.1 Bausch Health Profile
5.9.2 Bausch Health Main Business
5.9.3 Bausch Health Epilepsy Therapeutics Products, Services and Solutions
5.9.4 Bausch Health Epilepsy Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Bausch Health Recent Developments
5.10 Takeda
5.10.1 Takeda Profile
5.10.2 Takeda Main Business
5.10.3 Takeda Epilepsy Therapeutics Products, Services and Solutions
5.10.4 Takeda Epilepsy Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Takeda Recent Developments
6 North America
6.1 North America Epilepsy Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Epilepsy Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Epilepsy Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Epilepsy Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Epilepsy Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Epilepsy Therapeutics Market Dynamics
11.1 Epilepsy Therapeutics Industry Trends
11.2 Epilepsy Therapeutics Market Drivers
11.3 Epilepsy Therapeutics Market Challenges
11.4 Epilepsy Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
